8.23
Schlusskurs vom Vortag:
$8.20
Offen:
$8.24
24-Stunden-Volumen:
1.31M
Relative Volume:
0.51
Marktkapitalisierung:
$13.04M
Einnahmen:
$74,000
Nettoeinkommen (Verlust:
$-13.43M
KGV:
-0.8755
EPS:
-9.4
Netto-Cashflow:
$-10.54M
1W Leistung:
+95.95%
1M Leistung:
+2,249%
6M Leistung:
+44.53%
1J Leistung:
-70.61%
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Firmenname
Cyclacel Pharmaceuticals Inc
Sektor
Branche
Telefon
908-517-7330
Adresse
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Vergleichen Sie CYCC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CYCC
Cyclacel Pharmaceuticals Inc
|
8.23 | 6.65M | 74,000 | -13.43M | -10.54M | -9.40 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
2020-04-27 | Fortgesetzt | ROTH Capital | Buy |
2018-09-07 | Eingeleitet | Ladenburg Thalmann | Buy |
2015-10-16 | Eingeleitet | H.C. Wainwright | Buy |
2010-02-04 | Eingeleitet | Roth Capital | Buy |
2009-10-28 | Eingeleitet | Merriman | Buy |
2008-08-12 | Eingeleitet | Piper Jaffray | Buy |
2008-03-12 | Bestätigt | Cantor Fitzgerald | Buy |
2008-03-12 | Bestätigt | Collins Stewart | Buy |
2008-03-12 | Bestätigt | Needham & Co | Buy |
2007-11-27 | Bestätigt | Cantor Fitzgerald | Buy |
2007-08-10 | Bestätigt | Cantor Fitzgerald | Buy |
2007-06-04 | Bestätigt | Needham & Co | Buy |
2007-04-23 | Eingeleitet | Lazard Capital | Buy |
2007-04-10 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Cyclacel Pharmaceuticals Inc Aktie (CYCC) Neueste Nachrichten
Big Moves And Bigger Questions For Biotech And Tech Stocks - Finimize
Cyclacel stock falls after paring 270% gain amid volatility concerns By Investing.com - Investing.com Canada
Cyclacel stock dips after trimming 270% surge amid volatility concerns - MSN
Cyclacel Shares Plunge 36% Amid Volatility, What's Driving the Sell-Off? - AInvest
Cyclacel stock falls after paring 270% gain amid volatility concerns - Investing.com Australia
Cyclacel Pharmaceuticals Addresses Recent Stock Price Volatility Amid Ongoing Business Developments - Quiver Quantitative
CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY - Yahoo Finance
Cyclacel Pharmaceuticals Stock Plunges 37.23% - AInvest
Cyclacel Pharmaceuticals Stock Surges Amid Positive Research Findings - AInvest
What makes Cyclacel Pharmaceuticals Inc. stock price move sharplyHigh Potential Stock Ideas - beatles.ru
Why Cyclacel Pharmaceuticals Inc. stock attracts strong analyst attentionMarket Beating Strategy - Newser
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
Cyclacel's Volatile Surge: Can This Biotech Stock Defy Gravity? - AInvest
Cyclacel Pharmaceuticals Stock Soars: Investing or Waiting? - timothysykes.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Fitters: US$1m cash added to Cyclacel deal to address stock volatility since signing - The Malaysian Reserve
Cyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERS - MSN
Cyclacel stock soars after amendment to exchange agreement with FITTERS By Investing.com - Investing.com Nigeria
Cyclacel stock soars after amendment to exchange agreement with FITTERS - Investing.com Australia
Cyclacel sweetens Fitters acquisition deal with US$1m cash addition - The Malaysian Reserve
Cyclacel Pharmaceuticals Amends Exchange Agreement with FITTERS - TipRanks
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - The Manila Times
Breakthrough: New Drug Shows Effectiveness Against Untreatable Youth Liver Cancer, Research Reveals - Stock Titan
Cyclacel Pharmaceuticals adjusts shareholder rights, amends stock - MSN
Cyclacel Pharmaceuticals to Acquire Fitters Sdn. Bhd. Through Share Exchange Agreement - Global Legal Chronicle
Cyclacel Pharmaceuticals Announces 1-for-15 Reverse Stock Split Effective July 7, 2025 - Nasdaq
Cyclacel Pharmaceuticals Announces Stock Split - Morningstar
Cyclacel Pharmaceuticals to Implement 1-for-15 Reverse Stock Split; Shares Fall - MarketScreener
Cyclacel Pharmaceuticals shareholders re-elect directors and approve equity plan changes - Investing.com
Cyclacel Pharmaceuticals Approves Equity Plan Amendment - TipRanks
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock - Yahoo Finance
Why Did Cyclacel Pharmaceuticals Inc. (CYCC) Soar 13.92%? - AInvest
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Listing Rule - marketscreener.com
Cyclacel Pharmaceuticals Declares Quarterly Cash Dividend - TipRanks
Cyclacel Pharmaceuticals (CYCC) Regains Nasdaq Compliance | CYCC Stock News - GuruFocus
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM - GuruFocus
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement - marketscreener.com
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT | CYCC Stock News - GuruFocus
Cyclacel Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq
Cyclacel Dodges Delisting Risk: Stock Stabilizes Above $1, Secures Crucial Nasdaq Compliance - Stock Titan
Comparing Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Biodexa Pharmaceuticals (NASDAQ:BDRX) - Defense World
Cyclacel stock plunges to 52-week low of $1.95 amid market challenges - Investing.com Australia
(CYCCP) Proactive Strategies - news.stocktradersdaily.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - The Manila Times
Cyclacel Pharmaceuticals Reports Q1 2025 Financial Results and Strategic Focus Shifts to Plogosertib Development - Nasdaq
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
Fitters Clarifies Details Of Business Unit Disposal To Cyclacel - BusinessToday Malaysia
Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Monday - Defense World
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com - Defense World
Trend Tracker for (CYCCP) - news.stocktradersdaily.com
Finanzdaten der Cyclacel Pharmaceuticals Inc-Aktie (CYCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):